Validation of a survival-risk score (SRS) in relapsed/ refractory CLL patients treated with idelalisib–rituximab
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab
Tripepi Giovanni;D'Arrigo Graziella;
2020
Abstract
Validation of a survival-risk score (SRS) in relapsed/ refractory CLL patients treated with idelalisib–rituximabFile in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
41408_2020_Article_358.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
562.47 kB
Formato
Adobe PDF
|
562.47 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
